

Role of Intravenous Magnesium Sulphate in Term Neonates with Hypoxic Ischemic Encephalopathy (HIE) in a Low-income Country: A Randomised Clinical Trial

Muhammad Asif Siddiqui and Tayyaba Khawar Butt

Department of Paediatric Medicine Unit-II, Services Hospital, Lahore, Pakistan

ABSTRACT

Objective: To determine the effects of magnesium sulphate in term neonates with hypoxic ischemic encephalopathy (HIE) in reducing mortality and morbidity.

Study Design: Randomised clinical trial.

Place and Duration of Study: Department of Neonatology, Services Hospital, Lahore, Pakistan from April to December 2019.

Methodology: Term babies (inborn or outborn), fulfilling the operational definition of hypoxic ischemic encephalopathy, reaching within 6 hours of delivery in Nursery Department of Pediatric Medicine Unit-II, Services Hospital, Lahore, were included. Sarnat score was used for staging the severity of HIE. Cases were administered magnesium sulphate (MgSO₄) as intravenous infusion. Rest of the management was similar for cases and controls. Mortality was defined as death due to birth asphyxia; whereas, morbidity was assessed by comparing the following at discharge: the grade of hypoxic ischemic encephalopathy, presence and frequency of seizures, duration of seizures, ability to suck feed and neurological problems such as abnormalities of muscle tone and neonatal reflexes. Babies with prematurity, dysmorphism comorbidities or arriving after 6 hours of birth, were excluded. Chi-square test was used for comparison; and p value <0.05 was considered significant.

Results: Gender, mode of delivery, mode of resuscitation at birth, major risk factors (prolonged labour, premature rupture of membranes, presence of meconium-stained amniotic fluid) were comparable in both groups. The duration of seizures, ability to suck feed and presence of neurological problems at discharge were significantly better in magnesium sulphate group as compared to control group.

Conclusion: Magnesium sulphate is better in establishing earlier suck feed and reducing the duration of seizures and neurological problems in babies with birth asphyxia.

Key Words: Hypoxic ischemic encephalopathy, Magnesium sulphate, Outcome, Term, Low income country

How to cite this article: Siddiqui MA, Butt TK. Role of Intravenous Magnesium Sulphate in Term Neonates with Hypoxic Ischemic Encephalopathy (HIE) in a Low-income Country: A Randomised Clinical Trial. *J Coll Physicians Surg Pak* 2021; **31(07)**:817-820.

INTRODUCTION

In Pakistan, neonatal mortality and morbidity is remarkably high. Birth asphyxia is one of the main contributors to this, apart from prematurity, sepsis and other causes.^{1,2} Birth asphyxia is not only responsible for mortality, but also for short term and long-term neurological complications. Moderate to severe birth asphyxia is responsible for about 40% mortality and morbidity.³⁻⁵

Though hypothermia therapy or hypothermia with other adjunct therapies, like magnesium sulphate, has been recommended in moderate to severe hypoxia; but there is no optimal treatment modality available for birth asphyxia in low-income resource-deprived settings, apart from giving supportive and symptomatic treatment.⁶ Although hypothermia is an established treatment, lack of trained nursing staff is a hindrance in implementing it on a wide scale. Magnesium sulphate is cost-effective and readily available, and is easily administered in comparison to cooling therapy. Because of the relative ease with which it can be used, it may have a beneficial role in management of HIE even in resource-deprived neonatal units. Despite its potential benefit, very few local studies are available on its use.

The objective of this study was to determine the beneficial effects if any, of magnesium sulphate in term neonates with birth asphyxia in terms of morbidity and mortality.

Correspondence to: Dr. Muhammad Asif Siddiqui, Department of Paediatric Medicine Unit-II, Services Hospital, Lahore, Pakistan
E-mail: drmasifrmc@gmail.com

Received: April 08, 2021; Revised: June 09, 2021;
Accepted: June 25, 2021
DOI: <https://doi.org/10.29271/jcpsp.2021.07.817>

METHODOLOGY

It was a randomised clinical trial, conducted in Department of Neonatology, Services Hospital, Lahore from April to December 2019 with total duration of 8 months, after getting approval from Institutional Review Board (IRB/2019/527/SIMS) and Clinical Registry No. NCT04705142. Hypoxic ischemic encephalopathy was defined as need for neonatal resuscitation (rather than stabilisation) at birth with APGAR scores (≤ 3 in 1 minute and ≤ 7 in 5 minutes). Sarnat scoring was used to grade the severity of hypoxic ischemic encephalopathy (HIE). Mortality was defined as death due to birth asphyxia; whereas, morbidity was assessed by comparing the grade of hypoxic ischemic encephalopathy, frequency of seizures, duration of seizures, ability to suck feed, and neurological problems such as hypotonia/hypertonia, diminished neonatal reflexes at discharge.

All term inborn/outborn babies, reaching within 6 hours of delivery to Department of Neonatology, Services Hospital and fulfilling the operational definition of HIE, were included. Babies with prematurity, dysmorphism and comorbidities, were excluded. Written consent was taken from parents of the babies. This was a single-blinded study. Lottery method was used for randomisation. Cases (Group 1) were given magnesium sulphate with dose of 250mg/kg diluted in 10ml 10% D/W over 30 minutes in slow infusion at admission, at 24 hours of life and at 48 hours of life, with monitoring vitals (pulse rate, respiratory rate, blood pressure, oxygen saturation, capillary refill time) during and after administration, every 10 minutes. In case of any side effect related to magnesium sulphate, normal saline bolus, calcium gluconate, dopamine, or ventilatory support was provided as per ward policy. Baseline serum magnesium level was done before first dose than at day 2, day 3, and day 4. Controls (group 2) received similar supportive and symptomatic treatment with regular monitoring as control group. All data were taken on pre-designed proforma. SPSS version 23 was used to analyse the data. The data were expressed with frequencies and percentages. Chi-square test was used, and value less than 0.05 was taken as significant.

RESULTS

Forty babies were included in group 1 (Magnesium sulphate/case group) and 40 babies in group 2 (control group), after excluding one baby due to comorbid condition (congenital heart disease). Two babies (one in each group) left against medical advice (consort flow diagram Figure 1).

In order to minimise bias, the authors compared gender, mode of delivery, mode of resuscitation at birth and major risk factors (prolonged labour, premature rupture of membranes, meconium-stained amniotic fluid) between two groups; and found no difference (p value > 0.05). However, the weight for gestation was significantly lower in the control group (p -value < 0.05 ; Table I).

Comparing outcomes in both groups, duration of seizures, suck feed at discharge, neurological status at discharge were significantly better in group 1 (magnesium sulphate group). Whereas,

grade of HIE, frequency of seizures at discharge, and mortality were comparable in both groups (Table I). No side effects were noted related to intravenous magnesium sulphate infusion; likewise no significant variability in magnesium sulphate serum level detected between the two groups.




Figure 1: Consort 2010 flow diagram.

DISCUSSION

Neonatal mortality rate is very high in Pakistan; and birth asphyxia is one of the main contributors.^{1,2} Most units provide supportive and symptomatic care to babies with HIE due to resource limitations. Although body cooling is of definite benefit, most units in resource-limited settings are unable to provide it, because of lack of manpower in terms of numbers and training. Magnesium sulphate is cost-effective, readily available therapy with potential benefit in babies with HIE. However, sufficient local data is not available. Therefore, the authors felt the need to conduct this study to determine its safety and efficacy in resource limited settings

Magnesium sulphate use in HIE with hypothermia and other adjunct therapies is well established and it has shown improvements in short term outcomes with good safety profile. However, it has not shown significant improvement in long term outcomes and mortality.⁷⁻¹⁴

Internationally, there are many studies to support magnesium sulphate as monotherapy along with supportive care in HIE. Many of them showed short term beneficial effects in terms of reducing the duration of seizures, early establishment of suck feed, better short-term neurological outcomes.^{7,9,14-16} This study also showed similar results in terms of reduction in duration of seizures, early establishment of suck feed, better tone and neonatal reflexes in the absence of significant side effects. However, mortality, grade of HIE, frequency and presence of seizures were similar in both groups. Other patient characteristics, like gender, mode of delivery, major risk factors and mode of resuscitation, were comparable in both groups. Majority of babies were delivered by C-section with major risk factor being fetal distress or premature rupture of membranes.

Table I: Frequencies and p value of case group vs. control group.

Parameter	Parameter category	Cases	Control	p-value
Gender	Male	20(50%)	21(52.5%)	0.823
	Female	20(50%)	19(47.5%)	
Mode of delivery	SVD*	12(30%)	17(42.5%)	0.336
	c-section	27(67.5%)	23(57.5%)	
	Assisted vaginal delivery	1(2.5%)	0(0%)	
Risk factors	Meconium-stained liquor	8(20%)	7(17.5%)	0.968
	PROM*	9(22.5%)	8(20%)	
	Prolonged labor	14(35%)	16(40%)	
	Others	9(22.5%)	9(22.5%)	
Weight for gestation	AGA*	29(72.5%)	27(67.5%)	0.047
	SGA*	4(10%)	11(27.5%)	
	LGA*	7(17.5%)	2(5%)	
Resuscitation	PPV* with mask	18(45%)	22(55%)	0.323
	PPV with ETT*	8(20%)	10(25%)	
	PPV with ETT & chestcompression	14(35%)	8(20%)	
HIE* Grade	I	5(12.5%)	6(15%)	0.276
	II	20(50%)	13(32.5%)	
	III	15(37.5%)	21(52.5%)	
Seizures	Present	31(77.5%)	33(82.5%)	0.576
Frequency of seizures	Single	9(22.5%)	6(15%)	0.663
	Multiple	22(55%)	23(57.5%)	
Duration of seizures	<48 hours	10(25%)	2(5%)	0.043
	>48 hours	15(37.5%)	19(47.5%)	
Suck feed at discharge	Present	27(67.5%)	16(40%)	0.004
Neurological status	Normal	26(65%)	15(37.5%)	0.007
Outcome	Survived	30(75%)	26(65%)	0.329
	Expired	10(25%)	14(35%)	

SVD: Spontaneous vaginal delivery, PROM: Premature rupture of membranes, AGA: Appropriate for gestational age, SGA: Small for gestational age, LGA: Large for gestational age, PPV: Positive pressure ventilation, ETT: Endotracheal tube, HIE: Hypoxic ischemic encephalopathy.

Final analysis revealed a significantly greater number of small for gestational age neonates in the control group, which may lead to possible bias in the outcome.

Although there were only those babies who were less than 6 hours of age at admission, some studies have reported significant reduction in mortality and other beneficial effects of magnesium sulphate, even if given between 6 to 24 hours of life.^{17,18}

Regional studies also report significant role of magnesium sulphate in reducing the seizures duration and early establishment of suck feed. However, not all researchers have addressed the possible confounding factors.^{15,16,19-22}

Limitations of this study include small sample size, significant difference in weight for gestation between the two groups, and absence of long-term follow-up of neuro-developmental outcomes in babies who survived in both groups.

CONCLUSION

Magnesium sulphate is safe and has beneficial effects in establishing earlier suck feed, control of seizures, and better neurological status at discharge. It may be included in the routine management of babies, especially in resource-limited nurseries. However, further studies are required to see long term advantage of MgSO₄.

ETHICAL APPROVAL:

Ethical approval was obtained before start of study with

reference No. IRB/2019/527/SIMS from Institutional Review Board (IRB) of Services Institute of Medical Sciences, Lahore.

PATIENTS' CONSENT:

Patients' consents were obtained from the parents of the babies before enrolling them in the study.

CONFLICT OF INTEREST:

The authors declared no conflict of interest.

AUTHORS' CONTRIBUTION:

MAS, TKB: Conception, design of the work, analysis, interpretation of data, drafting, critical revision, and final approval of version to be published.

ACKNOWLEDGEMENT:

Dr. Fatima Tahira (Assistant Professor of Pediatrics, Pediatric Medicine, Services Hospital, Lahore) helped in collection of data.

REFERENCES

1. Aghai ZH, Goudar SS, Patel A, Saleem S, Dhaded SM, Kavi A, et al. Gender variations in neonatal and early infant mortality in India and Pakistan: A secondary analysis from the Global Network Maternal Newborn Health Registry. *Reprod Health* 2020; **17**(3):178. doi.org/10.1186/s12978-020-01028-0.
2. Ahmed M, Won Y. Cross-national systematic review of neonatal mortality and postnatal newborn care: Special focus on Pakistan. *Int J Environ Res Publ Health* 2017;

- 14(12).** doi: 10.3390/ijerph14121442.
3. Midan DA, Researcher I, View P. Oral allopurinol for preventing mortality and morbidity in neonates with moderate hypoxic ischemic encephalopathy. 2017;(April).
4. Yıldız EP, Ekici B, Tatlı B. Neonatal hypoxic ischemic encephalopathy: An update on disease pathogenesis and treatment. *Expert Rev Neurother* 2017; **17(5)**:449-59. doi.org/ 10.1080/14737175.2017.1259567.
5. Shamaoon M, Razzaq N, Ahsan M, Ahmad A, Maqbool T, Chaudhary AJ. Electrolyte imbalance in neonates with hypoxic ischemic encephalopathy: A single center study. *Prof Med J* 2020; **27(10)**:2159-64. doi: http://doi.org/10.29309/TPMJ/2020.27.10.4128.
6. Zen Lee CY, Chakranon P, Huey Lee SW. Comparative efficacy and safety of neuro-protective therapies for neonates with hypoxic ischemic encephalopathy: A network meta-analysis. *Front Pharmacol* 2019; **10**:1221. doi: 10.3389/fphar.2019.01221.
7. Lingam I. Magnesium sulphate neuroprotection in neonatal encephalopathy. 2020.
8. Anabrees J. Magnesium sulphate for newborns with HIE; synopsis of evidence from a systematic review. *J Clin Neonatol* 2013; **2(3)**:114-6. doi: 10.4103/2249-4847.119989.
9. Lingam I, Robertson NJ. Magnesium as a neuroprotective agent: A review of its use in the fetus, term infant with neonatal encephalopathy, and the adult stroke patient. *Dev Neurosci* 2018; **40(1)**:1-12. doi: 10.1159/000484891.
10. Nair J, Kumar VHS. Current and emerging therapies in the management of hypoxic ischemic encephalopathy in neonates. *Children (Basel)* 2018; **5(7)**:99. doi: 10.3390/children5070099.
11. Montaldo P, Lally PJ, Oliveira V, Swamy R, Mendoza J, Atreja G, et al. Therapeutic hypothermia initiated within 6 hours of birth is associated with reduced brain injury on MR biomarkers in mild hypoxic-ischaemic encephalopathy: A non-randomised cohort study. *Arch Dis Child Fetal Neonatal Ed* 2018; **104(5)**:F515-F520. doi: 10.1136/archdischild-2018-316040.
12. El Farargy MS, Soliman NA. A randomised controlled trial on the use of magnesium sulfate and melatonin in neonatal hypoxic ischemic encephalopathy. *J Neonat Perinat Med* 2020; **12(4)**:379-84. doi: 10.3233/NPM-181830.
13. Nonomura M, Harada S, Asada Y, Matsumura H, Iwami H, Tanaka Y, et al. Combination therapy with erythropoietin, magnesium sulfate and hypothermia for hypoxic-ischemic encephalopathy: An open-label pilot study to assess the safety and feasibility. *BMC Pediatr* 2019; **19(1)**:13. doi: 10.1186/s12887-018-1389-z.
14. Ichiba H, Tamai H, Negishi H, Ueda T, Kim TJ, Sumida Y, et al. Randomised controlled trial of magnesium sulfate infusion for severe birth asphyxia. *Pediatr Int* 2002; **44(5)**: 505-9. doi: 10.1046/j.1442-200x.2002.01610.x.
15. Sreenivasa B, Lokeshwari K, Joseph N. Role of magnesium sulphate in management and prevention of short term complications of birth asphyxia. *Sri Lanka J Child Heal* 2017; **46(2)**:148-51.
16. Riyaz Ahmed FK, Shrikanth SN. Evaluation of safety of magnesium of sulphate therapy in neonates with birth asphyxia. *Int J Contemp Pediatr* 2016; **3(1)**:80-5. doi: http://dx.doi.org/10.18203/2349-3291.ijcp20160095.
17. Pius S, Bello M, Ambe JP, Yenti M, Genesis R, Clement AY, et al. Magnesium sulphate treated severely asphyxiated neonates, their characteristic and outcome. *Asian J Pediatr Res* 2019; **1(July 2018)**:1-9.
18. Okonkwo I, Okolo A. Postnatal magnesium sulfate in asphyxiated newborns in benin city nigeria: Effect on mortality. *Int J Pediatr Neonatal Care* 2018; **4(1)**. doi:10.15344/2455-2364/2018/136.
19. Savitha MR, Rajprakash. Beneficial effect of intravenous magnesium sulphate in term neonates with perinatal asphyxia. *Int J Contemp Pediatr* 2016; **3(1)**:150-4. doi.org/10.18203/2349-3291.ijcp20160149
20. Muhammad H, Ahmad I. Role of magnesium sulphate in newborns with birth asphyxia. *J Med Physiol Biophys* 2019; **54**:115-8.
21. Sajid NK, Junaid M, Ahmed S. Therapeutic efficacy of magnesium sulphate on neurological outcome of neonates with severe birth asphyxia. *J Univ Med Dent Coll* 2018; **9(4)**:1-5. Available from: http://www.jumdc.com/index.php/jumdc/article/view/95.
22. Rashid A, Fatima N, Asim M, Khalid A, Ali AS. Role of magnesium sulphate in short term neurological outcome of perinatal asphyxia. *Pakistan Postgrad Med J* 2015; **26(1)**:1-5.

• • • • •